Drug
Mirdametinib OR Dispersible
Mirdametinib OR Dispersible: highest development phase Phase 2, developed by Merck. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Merck
Trials
| Drug | Phase | Indication |
|---|---|---|
| Mirdametinib (PD-0325901) oral capsule or dispersible tablet NCT03962543 | Phase 2 | Plexiform Neurofibroma |
Latest
No recent events.
Follow Mirdametinib OR Dispersible on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.